Study Confirms Transave’s Antibiotic May Reduce Pseudomonas

April 3, 2008

Transave Inc., a biopharmaceutical company focused on developing inhaled therapies for lung diseases, reported today that its lead product candidate, ARIKACE™ (liposomal amikacin for inhalation), may have the ability to penetrate mucus and decrease the number of Pseudomonas aeruginosa lung infections in patients with cystic fibrosis, according to a study published in the April issue of the Journal of Antimicrobial Chemotherapy. 

The Cystic Fibrosis Foundation provided a $1.7 million award for this clinical program.

Read the full press release.